TIGIT and cancer: T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) is a major inhibitory receptor of both T cells and natural killer (NK) cells (reviewed in [1,2,3]) and is an emerging target for immune checkpoint blockade for the treatment of cancer.